| Title |
Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
|
|---|---|
| Published in |
Journal of Translational Medicine, April 2018
|
| DOI | 10.1186/s12967-018-1471-1 |
| Pubmed ID | |
| Authors |
Iman W. Achkar, Nabeel Abdulrahman, Hend Al-Sulaiti, Jensa Mariam Joseph, Shahab Uddin, Fatima Mraiche |
| Abstract |
Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 155 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 10% |
| Student > Bachelor | 16 | 10% |
| Student > Ph. D. Student | 13 | 8% |
| Researcher | 11 | 7% |
| Lecturer | 7 | 5% |
| Other | 20 | 13% |
| Unknown | 72 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 27 | 17% |
| Medicine and Dentistry | 13 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 8% |
| Agricultural and Biological Sciences | 10 | 6% |
| Chemistry | 8 | 5% |
| Other | 13 | 8% |
| Unknown | 72 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2018.
All research outputs
#18,601,965
of 23,041,514 outputs
Outputs from Journal of Translational Medicine
#2,982
of 4,033 outputs
Outputs of similar age
#255,517
of 329,169 outputs
Outputs of similar age from Journal of Translational Medicine
#70
of 103 outputs
Altmetric has tracked 23,041,514 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,033 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,169 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 103 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.